JP Morgan Chase
GEVA

JP Morgan Chase’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

JP Morgan Chase’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-286,447
Closed -$27.9M – 4343
2015
Q1 		$27.9M Buy
286,447
+57,107
+25% +$6.05M 0.01% 1214
2014
Q4 		$21.3M Buy
229,340
+112,909
+97% +$8.91M ﹤0.01% 1430
2014
Q3 		$8.01M Sell
116,431
-1,800
-2% -$129K ﹤0.01% 2071
2014
Q2 		$12.4M Buy
118,231
+4,830
+4% +$411K ﹤0.01% 1629
2014
Q1 		$9.41M Buy
113,401
+50,875
+81% +$4.7M ﹤0.01% 1756
2013
Q4 		$4.05M Buy
62,526
+52,888
+549% +$3.14M ﹤0.01% 2307
2013
Q3 		$611K Sell
9,638
-8,361
-46% -$412K ﹤0.01% 3532
2013
Q2 		$756K Buy
+17,999
New +$820K ﹤0.01% 3419

JP Morgan Chase's GEVA Position: Q2 2015 in Review

JP Morgan Chase sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 286,447 shares — an estimated $27.9M sold.

JP Morgan Chase first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $27.9M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • JP Morgan Chase reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • JP Morgan Chase sold 286,447 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $27.9M.
  • JP Morgan Chase first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • JP Morgan Chase's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $27.9M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on JP Morgan Chase's 13F filing for Q2 2015, filed 14 Aug 2015.